Physician profile
Jeffrey Luk
NPI 1255742730
$2,356.20
in general payments reported to CMS, 2019-2025
19 companies · $441 in 2025
The $441 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $44.16 · 2021: $148 · 2022: $419 · 2023: $631 · 2024: $673 · 2025: $441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,716 · Education: $29.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,715.51 |
| Education | $29.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $493.73 | 2020-2025 | |
| Celgene Corporation | $457.75 | 2022-2024 | Zeposia |
| Janssen Biotech, INC. | $207.48 | 2021-2025 | Tremfya, Simponi Aria, Stelara |
| Pfizer INC. | $180.84 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $143.27 | 2023-2025 | Entyvio, Eohilia |
| Lilly USA, LLC | $106.44 | 2024-2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $87.97 | 2023-2024 | Dupixent |
| Nestle Healthcare Nutrition INC. | $86.18 | 2022-2023 | |
| Gilead Sciences, INC. | $84.65 | 2022-2023 | |
| Ipsen Biopharmaceuticals, INC | $79.61 | 2025 | Iqirvo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $75.30 | 2022-2024 | Xifaxan |
| Merck Sharp & Dohme LLC | $60.15 | 2023-2024 | Dificid |
| Aimmune Therapeutics, INC. | $59.86 | 2024-2025 | Zenpep |
| E.R. Squibb & Sons, L.L.C. | $53.41 | 2023 | Zeposia |
| Madrigal Pharmaceuticals | $49.99 | 2024-2025 | Rezdiffra, Resmetirom |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $37.29 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $36.79 | 2025 | Voquezna |
| Celltrion USA INC. | $29.60 | 2024 | Zymfentra |
| Organon LLC | $25.89 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Luk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.